antibody-drug conjugates

News

Genmab offers $1.8bn for ADC specialist ProfoundBio

Antibody developer Genmab has made a play to boost its expertise in the scalding hot area of antibody-drug conjugates (ADCs), agreeing a $1.8 billion deal to acquire Profo

News

Ipsen licenses Sutro ADC in $900m deal

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.

News

German biotech Tubulis raises €128m for ADC trials

Munich-based antibody-drug conjugate (ADC) specialist Tubulis has completed a sizeable Series B2 financing that shows sustained investor appetite for the ADC category, par

News

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan i

News

AZ, Daiichi eye December verdict for TROP2 ADC

The FDA has started a review of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan as a therapy for lung cancer, the second drug in their antibody-drug conjugate (ADC

News

DISCO dances out of the shadows with €20m for ‘surfaceome’

Germany has a new biotech, DISCO Pharmaceuticals, which has announced its presence with €20 million (around $22 million) in seed financing that will be used to advance its

Genmab offers $1.8bn for ADC specialist ProfoundBio

Ipsen licenses Sutro ADC in $900m deal

German biotech Tubulis raises €128m for ADC trials

EMA starts twin reviews of AZ, Daiichi’s Dato-DXd

AZ, Daiichi eye December verdict for TROP2 ADC

DISCO dances out of the shadows with €20m for ‘surfaceome’

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

antibody-drug conjugates

Editor's Picks